NPTXOTCHealthcare · Biotechnology

Neuropathix, Inc.

$0.00+0.00%(+$0.00)

TickerSpark Score

53/100

Mixed

Valuation

Profitability

Growth

Health

Momentum

Built from real-time financials and updated daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a NPTX research report →

52-Week Range0% of range

Low $0.00

Current $0.00

High $0.04

Companyneuropathix.com

Neuropathix, Inc. , a biopharmaceutical company, focuses on the discovery, development, and commercialization of novel therapeutics from its proprietary synthetic cannabinoid derivatives platform. It engages in the research and development of chemical entities, such as KLS-13019, KLS-13023, and KLS-13022, as well as its related molecules; and synthetic cannabidiol therapeutics through pre-clinical drug discovery and development processes for use in the disease indications of chemotherapy induced peripheral neuropathy, overt hepatic encephalopathy, mild traumatic brain injury, and chronic traumatic encephalopathy.

CEO: Dean Petkanas
IPO: 2019
Employees: 6
HQ: Doylestown, PA, US

Price Chart

-98.57% · this period

Valuation

Market Cap: $28.14K
P/E: -0.01
P/S: 0.15
P/B: -0.01
EV/EBITDA: -0.66
Div Yield: 0.00%

Profitability

Gross Margin: 100.00%
Op Margin: -1602.73%
Net Margin: -2175.95%
ROE: 111.19%
ROIC: 217.12%

Growth & Income

Revenue: $183.48K · 0.00%
Net Income: $-3,992,375 · 28.32%
EPS: $-0.05 · 38.87%
Op Income: $-2,940,636
FCF YoY: 5.09%

Performance & Tape

52W High: $0.04
52W Low: $0.00
50D MA: $0.00
200D MA: $0.01
Beta: 1.65
Avg Volume: 13.60K

Get TickerSpark's AI analysis on NPTX

Pro members can request AI-generated analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.

Get Pro Access →

30-day money-back guarantee · cancel anytime

Recent Insider Transactions

Date	Insider	Role	Type	Shares	Value
Jun 6, 22	PETKANAS DEAN	director, 10 percent owner, officer: Chief Executive Officer	sell	10,000	$250
Jun 7, 22	PETKANAS DEAN	director, 10 percent owner, officer: Chief Executive Officer	sell	50,000	$1.00K
Jun 8, 22	PETKANAS DEAN	director, 10 percent owner, officer: Chief Executive Officer	sell	21,836	$458.556
Jun 9, 22	PETKANAS DEAN	director, 10 percent owner, officer: Chief Executive Officer	sell	238,164	$5.00K
Jun 13, 22	PETKANAS DEAN	director, 10 percent owner, officer: Chief Executive Officer	other	300,000	$4.83K
Jun 13, 22	PETKANAS DEAN	director, 10 percent owner, officer: Chief Executive Officer	other	100,000	$1.61K
May 26, 22	PETKANAS DEAN	director, 10 percent owner, officer: Chief Executive Officer	sell	100,000	$2.60K
May 27, 22	PETKANAS DEAN	director, 10 percent owner, officer: Chief Executive Officer	sell	50,000	$1.45K
May 31, 22	PETKANAS DEAN	director, 10 percent owner, officer: Chief Executive Officer	sell	10,000	$280
May 31, 22	PETKANAS DEAN	director, 10 percent owner, officer: Chief Executive Officer	sell	20,000	$520